atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference | Psychedelic Invest

NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) — atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements. Scott…

Matt & Adam’s Take: Amylyx did the right thing by withdrawing its ALS drug. That’s rare and worthy of praise

On Thursday morning, Amylyx Pharmaceuticals announced that it would withdraw its ALS drug, Relyvrio, after a large clinical trial showed that the medicine, approved by

April 4, 2024

Colorado to allow additional public input on planned expansion of gas storage near Adams County elementary school – The Cannabist

Related Articles Colorado air pollution regulators made the rare move this month to extend the public comment period on a permit that would allow a

August 10, 2024

New Teva ad campaign focuses on patients struggling with psychiatric drug side effect

Teva is focused on growing its Austedo brand to treat tardive dyskinesia, a side effect of some mental health medications, jumpstarting this year with a

February 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.